Novartis leadership reshuffle brings Biogen Idec talent to Sandoz
This article was originally published in Scrip
Executive Summary
Jeff George, head of Novartis's generics business Sandoz since December 2008, is to take over the leadership of its eye care business Alcon. He will replace the retiring Kevin Buehler, who has been with the company for 30 years. Mr George's replacement at Sandoz is Biogen Idec's senior vice president, US commercial operations, Richard Francis.